Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Ltd, a biopharmaceutical company specializing in novel immunotherapies for cancer, has fully subscribed to a EUR 30.7 million share offering, with new shares now trading on First North and AIM. The settlement of the shares under the UK Open Offer was slightly delayed but is expected to complete shortly. The company’s lead product, bexmarilimab, is currently in Phase I/II clinical trials and aims to reprogram immune cells to improve anti-tumor responses.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
